you sold and management and major shareholders increased their holdings again. 35 million dollar market cap when it should be at a 100 million market cap in line with its peers and the success of NA-1 on a 10 min infusion proving up calcium influx reduced brain injury in humans already. AGN going to prove up the same thing in humans shortly as well.
With NYR being the only drug in the world for secondary brain injury and cardiovascular protection working simultaneously and now in humans CEO stating last week big pharma are now looking at NYR well the rest takes care of itself. In 12 months time they will be in the same position as Aptoll on a multi billion dollar licence agreement
NYR Price at posting:
17.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)